Search - tctmd.com

Displaying 121 - 140 of 231

Sort: Relevancy | Date

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

December 17, 2018

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

December 07, 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

News Industry News

Veryan Medical receives PMA approval for BioMimics 3D

October 05, 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

May 08, 2018

Same-Day Discharge After Peripheral Interventions Gets Mixed Results in Pilot Study

News Daily News

Same-Day Discharge After Peripheral Interventions Gets Mixed Results in Pilot Study

March 22, 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

March 12, 2018

High Rate of Amputation and Death after Major Adverse Limb Events (MALE) in Peripheral Artery Disease: Results from COMPASS

Presentation ACC 2018

High Rate of Amputation and Death after Major Adverse Limb Events (MALE) in Peripheral Artery Disease: Results from COMPASS

Presenter: Sonia S. Anand

March 11, 2018

Noninvasive Testing of CLI: Many Ways to Draw Up a ‘Roadmap’

News Conference News ISET 2018

Noninvasive Testing of CLI: Many Ways to Draw Up a ‘Roadmap’

February 05, 2018

Burden of Readmission High in PAD Patients Following Revascularization

News Daily News

Burden of Readmission High in PAD Patients Following Revascularization

December 04, 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

August 03, 2017

Artificially Created Thrombus May Aid in Cases of Endovascular Perforation

News Daily News

Artificially Created Thrombus May Aid in Cases of Endovascular Perforation

July 25, 2017

News Daily News

Wingman35 Crossing Catheters Recalled Due to Tip Splitting, Separation

May 04, 2017

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

May 03, 2017

Most PAD Patients ‘Dramatically Undertreated’ With Preventive Meds, Lifestyle Counseling

News Daily News

Most PAD Patients ‘Dramatically Undertreated’ With Preventive Meds, Lifestyle Counseling

May 01, 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

News Conference News ISET 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

February 15, 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

News Conference News ISET 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

February 07, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.